This approval was followed by Takeda Pharmaceuticals’ Alofisel (darvadstrocel), which received approval from the European Medicines Agency in 2018 and from Japan’s Pharmaceuticals and Medical Devices ...
The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...
Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
U.S. President Donald Trump said on Monday he will in the very near future announce tariffs on automobiles, aluminum and ...
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating resp ...
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...
MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight ...
22h
Victory Capital Management Inc. purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) ...
StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from a hold rating to a buy rating ...
Milestone Pharmaceuticals faces a pivotal FDA PDUFA decision for etripamil in PSVT. Read here for a detailed investment ...
Learn more about whether PennyMac Financial Services, Inc. or Rocket Companies, Inc. is a better investment based on AAII's ...
Biotech and biopharma companies have battled with a drought of private investment in recent years but could now face ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback